{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(6)"],"submitter":["Gagliardini R"],"pubmed_abstract":["<h4>Background</h4>Dual therapy (DT) with boosted protease inhibitors (bPIs) plus lamivudine has been shown to be superior to bPI monotherapy in virologically suppressed patients despite previous selection of the lamivudine resistance M184V mutation. We compared the virological efficacy of lamivudine-based DT in patients with and without a history of M184V detection.<h4>Methods</h4>We retrospectively analyzed patients with HIV-RNA ≤50 copies/mL switching to DT with at least 1 previous resistance genotype in the ARCA database. Time to virological failure (VF; HIV-RNA ≥200 copies/mL or 2 consecutive HIV-RNA >50 copies/mL) and to treatment discontinuation (TD) was analyzed by survival analysis.<h4>Results</h4>Four hundred thirty-six patients switching to lamivudine plus bPIs (70%) or integras"],"journal":["Open forum infectious diseases"],"pagination":["ofy113"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6016422"],"repository":["biostudies-literature"],"pubmed_title":["Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study."],"pmcid":["PMC6016422"],"pubmed_authors":["Magnani G","Penco G","Rita Gismondo M","Gianotti N","Polilli E","Degiuli A","Zerbini A","Parruti G","Maserati R","Milini P","Rusconi S","Tosti A","Tacconi D","Borghetti A","Zanussi S","Malandrin S","Maggiolo F","Cascio A","De Luca A","Mellace V","Turriziani O","Galli L","Borghi V","Andreoni M","Punzi G","Sacchini D","Ghisetti V","Nerli A","Zoncada A","Gagliardini R","Montano M","Baldelli F","Callegaro AP","Soria A","Bruzzone B","Vivarelli A","Setti M","Bartolozzi D","Bagnarelli P","Nencioni C","Paolucci S","Pecorari M","Francisci D","Boeri E","Calzetti C","Vullo V","Zazzi M","Malena M","Baldanti F","Corsi P","Pardelli R","Capetti A","Saladini F","Cosco L","Ciccullo A","Paolini E","Foca A","De Gennaro M","Grossi P","ARCA Study Group","Sighinolfi L","Di Biagio A","Micheli V","Lenzi L","Filice G","Lombardi F","Mondino V","Blanc P","Meraviglia P","Callegaro A","Poletti F","Del Gobbo R","Monno L","Di Giambenedetto S","Bonora S","Surace L","Arcidiacono I","Cicconi P","Gonnelli A","Mussini C","Butini L","Luisa Biondi M","Giacometti A","Colao G"],"additional_accession":[]},"is_claimable":false,"name":"Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.","description":"<h4>Background</h4>Dual therapy (DT) with boosted protease inhibitors (bPIs) plus lamivudine has been shown to be superior to bPI monotherapy in virologically suppressed patients despite previous selection of the lamivudine resistance M184V mutation. We compared the virological efficacy of lamivudine-based DT in patients with and without a history of M184V detection.<h4>Methods</h4>We retrospectively analyzed patients with HIV-RNA ≤50 copies/mL switching to DT with at least 1 previous resistance genotype in the ARCA database. Time to virological failure (VF; HIV-RNA ≥200 copies/mL or 2 consecutive HIV-RNA >50 copies/mL) and to treatment discontinuation (TD) was analyzed by survival analysis.<h4>Results</h4>Four hundred thirty-six patients switching to lamivudine plus bPIs (70%) or integras","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-05-06T06:46:59.028Z","creation":"2019-03-26T23:45:07Z"},"accession":"S-EPMC6016422","cross_references":{"pubmed":["29977967"],"doi":["10.1093/ofid/ofy113"]}}